CHIKV

Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate

Retrieved on: 
星期二, 十二月 21, 2021
Mortality, Program, VLA, Marketing, Vaccination, Nasdaq, Genome, GMT, LMIC, GMT (TV programme), Alphavirus, Lyme disease, Infection, Priority review, Human, European Medicines Agency, Breakthrough therapy, Disease, Nausea, Confidence interval, PRV, Travel, Data monitoring committee, European, COVID-19, Ageing, Euronext Paris, Population, US Foods, EMA, Fever, Headache, BLA, Aedes, Company, Safety, Vaccine, Valneva SE, Food, Immunization, CHIKV, CEPI, Rash, FDA, DSMB, Pharmaceutical industry, Pfizer, Chikungunya

Saint Herblain (France), December 21, 2021 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.

Key Points: 
  • Saint Herblain (France), December 21, 2021 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.
  • All three lots were equally well tolerated and the safety profile was consistent with results in the pivotal Phase 3 trial.
  • The lot-to-lot trial will continue towards final six-month analysis with final trial results expected in the second quarter of 2022.
  • VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus, which has spread to more than 100 countries.

Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting

Retrieved on: 
星期一, 十一月 15, 2021
Society, Safety, Transactions of the Royal Society of Tropical Medicine and Hygiene, LMIC, VLA, Tropical medicine, European, MD, DSMB, Coalition, Data monitoring committee, Infection, CEPI, Lyme disease, Doctor of Philosophy, Ageing, Epidemic, Euronext Paris, Coalition for Epidemic Preparedness Innovations, COVID-19, Hygiene, GMT, Fatigue, Chikungunya, Global health, Myalgia, Travel, Saint-Herblain, Headache, Vaccine, Genome, Annual general meeting, Company, CHIKV, Fever, Vaccination, Marketing, Nasdaq, FDA, Pharmaceutical industry

Saint-Herblain (France), November 15, 2021 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present its Chikungunya vaccine candidate, VLA1553, on November 18 and 19, 2021 during the American Society of Tropical Medicine & Hygiene (ASTMH) 2021 Annual Meeting.

Key Points: 
  • Saint-Herblain (France), November 15, 2021 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present its Chikungunya vaccine candidate, VLA1553, on November 18 and 19, 2021 during the American Society of Tropical Medicine & Hygiene (ASTMH) 2021 Annual Meeting.
  • At the beginning of August 2021, Valneva announced positive topline results for the Phase 3 pivotal trial of VLA1553.
  • TropMed21, the ASTMH 2021 Annual Meeting, is the premier international forum for the exchange of scientific advances in tropical medicine, hygiene and global health and will be 100% virtual this year.
  • VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus, which has spread to more than 100 countries.

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

Retrieved on: 
星期五, 十月 15, 2021
Headache, Risk, Instagram, PRIME, Private Securities Litigation Reform Act, Solution, LinkedIn, Arthralgia, Social responsibility, Myalgia, Breakthrough therapy, European Medicines Agency, Chikungunya, SEC, Ageing, Marketing, Rash, NYSE, Disease, CHIKV, Patient, Public health, Life, Emergent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Vaccine, Food, SNA, Fast Track, Review, Twitter, Safety, Fever, EBS, VLP, Emergent BioSolutions, Pharmaceutical industry

GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the companys investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose.

Key Points: 
  • GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the companys investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose.
  • CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease.
  • Emergent has achieved a major milestone as we begin our phase 3 study for our single-dose chikungunya vaccine candidate, said Karen L. Smith, M.D., Ph.D., executive vice president and chief medical officer at Emergent BioSolutions.
  • Early this year, the company announced two-year persistence data from its Phase 2 safety and immunogenicity study of CHIKV VLP in 415 healthy adults.

Proactive news headlines including Horizon Minerals, Firefinch, Salt Lake Potash and Piedmont Lithium

Retrieved on: 
星期一, 九月 13, 2021
Lithium, PPS, BDC, Now, TMR, Research, PLOS, Proactivity, Gold, PLOS One, OTCQB, XETRA, LEG, Leo, NAL, Thorsby, NASDAQ, POS, Lac Minerals Ltd v International Corona Resources Ltd, PLL, Delta blues, Silver, GLOBE, SEO, CHIKV, CPH, TIN, Piedmont Lithium, MGV, HRZ, SYA, ASX, OTC, NTU, TSX, LSE, Alphavirus, Mining, Arthralgia, PAR, DB2, AIM, SOP, News, Oil, Rare-earth element, Iron ore, Public relations, Video game

Click here

Key Points: 
  • Click here
    Salt Lake Potash Ltd (AIM:SO4, ASX:SO4, OTC:WHELF, LSE:SO4) has appointed highly experienced mining executive Isak Buitendag as new CEO as it moves to progress its flagship Lake Way Sulphate of Potash (SOP) Project in Western Australia.
  • Click here
    Piedmont Lithium Inc (ASX:PLL, NASDAQ:PLL, XETRA:) and Sayona Mining Ltd (ASX:SYA) have confirmed the potential for a significant resource expansion at the newly acquired North American Lithium (NAL) mine in Qubec, Canada.
  • Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.
  • For more information on how Proactive can help you make a difference, email us at [email protected]